



*"Investing wisely in
healthcare innovation
for the benefit of society
and our members"*



December 2016

Members: 169

Countries: 13

Investments: 3

Impleo Tax Credit, Clinical Protocol

Officially Approved

For those who invested in Impleo, MedPro will facilitate the process of claiming your 25% rebate. We will be in communication guiding you on the process of securing your 25% rebate. As a preview of the process, each investor will need to file a report form by February 1. Then in mid-February, each investor will receive a tax credit certificate via email showing his/her tax credit amount. This certificate will be used to complete the final step, which is filing a Minnesota state tax return (as a non-resident if you do not reside there) to claim the rebate.

Earlier this week Impleo received confirmation from the USFDA that its protocol for the upcoming pivotal clinical trial had been approved. It is unusual for a protocol to be approved on the first submission.

Impleo is still looking to top up the investment round led by MedPro, so if any of you wish to invest or add to your investment in Impleo, please contact Steve@MedProinvestors.com at your

earliest convenience.

B-Temia Enters Commercialization Phase

Upward Trajectory

B-Temia sold over C\$1,000,000 worth of Keeogo™ devices in 2016. Just last week, B-Temia announced two new distributors, one in British Columbia and the other in Alberta. The company continues to expand its sales force while signing new distributor agreements. It has also established a training regimen which distributors and practitioners can use for their patients, and expanded its production capabilities extensively. Meanwhile, the U.S. clinical trial is progressing quickly and a submission to the FDA is expected early in the new year. The clinical trial includes use of Keeogo in both rehab facilities and in the patient's own home environment. The bulky exoskeletons such as ReWalk can only be used in supervised rehab facility settings. Positive news is also anticipated early next year regarding sales of the military version of Keeogo.

Immunomic Therapeutics

More Recognition

Immunomic won "Life Science Company of the Year", a distinction awarded to the company by the Tech Council of Maryland at one of the state's largest and most prestigious ceremonies aimed at recognizing the best executives, businesses and technology developed in Maryland and the surrounding regions. While Immunomic continues to be a success story and is well funded through late 2018/early 2019, the company feels additional capital will eventually be necessary and wants to take advantage of current investor appetite and is offering a \$10 million convertible note. Immunomic also recently strengthened its intellectual property portfolio by securing a new US patent that covers its out-licensed investigational DNA vaccines. A Phase II clinical trial in Glioblastoma is also progressing.

Next Up

Potential investments under consideration

More than a year has passed since the University of Pennsylvania walked away from year-long discussions regarding the licensing technology for the production of over 100 proteins and vaccines in genetically engineered lettuce. The University's tech transfer staff said that they intended to form their own company to develop the technology while licensing individual proteins to big pharma. MedPro has already formed Phyllo Pharma to manage the development of the technology and MedPro Management was quite disappointed when the University backed away from any licensing arrangement. In the past week, the University has come back to MedPro and offered to reopen negotiations. The proteins produced in lettuce emerge wrapped in a chloroplast which prevents their breakdown in the stomach. Traditionally, therapeutic proteins must be delivered by injection for this reason. Enabling the chlorophyll wrapped proteins to pass through the stomach and deliver the drug of interest in the intestine has very great importance. MedPro Management is also actively reviewing the merits of companies seen at various investor conferences. These include immune-oncology, infectious disease and cardiac diagnostic opportunities, to name a few.

It should be noted that our interests and capacity to evaluate opportunities in many fields of medical specialization, thanks to our specialist Members, is truly extensive. We welcome suggestions of financing opportunities from MedPro Members and friends. We seek companies with some demonstration of clinical efficacy which show promise of advancing the standard of care. Companies may be public or private.

MedGrow

Help us increase the size of our Membership

MedPro Investors LLC has grown to 169 healthcare professional Members. We expect to continue substantially increasing that number. Your connections and ability to help in this effort are extremely valuable. The larger we are, the more areas of expertise we can cover and the more we will be able to make significant investments in promising opportunities. The best sources of new Members are current MedPro Members. For this reason, we encourage you to recommend other healthcare professionals to join our ranks. Please do not hesitate to send us the names of any healthcare professional friends, colleagues or associates that come to mind. A simple list including names and email addresses can be sent to

steve@medproinvestors.com.



Visit Us:

<http://www.medproinvestors.com/>

Email Us:

isaac@medproinvestors.com

Call Us:

1-212-561-3611 (Steve)

Copyright © 2016 MedPro Investors LLC, All rights reserved.

[unsubscribe from this list](#) [update subscription preferences](#)
